Cargando…

Clinical Features and Prognostic Outcome of Renal Collecting Duct Carcinoma: 12 Cases from a Single Institution

PURPOSE: Collecting duct carcinoma (CDC) is extremely rare and has high malignancy and poor prognosis. The purpose of this research is to explore the clinical characteristic, imaging, pathological diagnosis, treatment and prognostic outcome of CDCs. MATERIALS AND METHODS: The clinical data of 12 CDC...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Xiaoyuan, Wang, Zhixian, Zhang, Jiaqiao, Wang, Qing, Zhou, Peng, Wang, Shaogang, Wang, Bo, Qian, Can
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245445/
https://www.ncbi.nlm.nih.gov/pubmed/32547196
http://dx.doi.org/10.2147/CMAR.S244094
_version_ 1783537760798244864
author Qian, Xiaoyuan
Wang, Zhixian
Zhang, Jiaqiao
Wang, Qing
Zhou, Peng
Wang, Shaogang
Wang, Bo
Qian, Can
author_facet Qian, Xiaoyuan
Wang, Zhixian
Zhang, Jiaqiao
Wang, Qing
Zhou, Peng
Wang, Shaogang
Wang, Bo
Qian, Can
author_sort Qian, Xiaoyuan
collection PubMed
description PURPOSE: Collecting duct carcinoma (CDC) is extremely rare and has high malignancy and poor prognosis. The purpose of this research is to explore the clinical characteristic, imaging, pathological diagnosis, treatment and prognostic outcome of CDCs. MATERIALS AND METHODS: The clinical data of 12 CDC cases who had been surgically treated between August 2007 and August 2017 and verified the diagnosis of CDC by postoperative pathological and/or immunohistochemical staining (IHC) results were retrospectively analyzed, and related works of literature were reviewed. And Kaplan-Meier survival analysis was used to draw the survival curve and to calculate the survival rate and the median survival time. RESULTS: According to the TNM stage system, 4 cases were in stage I, 2 in stage II,3 in stage III, and 3 in stage IV. On the computed tomograph and magnetic resonance imaging, CDC displayed that various shapes, unclear boundary and invasive growth into the renal parenchyma. Compared with small CDCs which did not change the contour of the kidney, large CDCs presented various imaging features. Microscopically, the typical morphology of CDCs was that collecting ducts or tubules were obviously infiltrated by tumor cells. A tubular, papillary, tubulopapillary or solid architectures with desmoplasia were often presented. And tumor cells had high-grade cytology or an infiltrative growth pattern. Necrosis of tumor cells also was common in many cases. The expression of biomarkers, such as PAX-8, INI-1, 34βE12, CK19, PAX-2, and vimentin, in most patients was detected by IHC. Eleven of all 12 cases received radical surgery, of whom 5 patients died 3–11 months after surgery, and 1 case having undergone interventional embolization therapy died at 6 months after treatment due to multiple metastases. And 1 lost to contact. The overall 1-, 2-, and 5-year survival rates were 45.5%, 36.4%, and 8.8%, respectively, and the median survival time (MST) was 11 months. CONCLUSION: CDC has an aggressive clinical course, with a poor prognosis. The best way to treat CDC suspected by imaging examinations is radical surgery which can contribute to confirm the correct histopathological type. And post-operation follow-up is necessary.
format Online
Article
Text
id pubmed-7245445
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72454452020-06-15 Clinical Features and Prognostic Outcome of Renal Collecting Duct Carcinoma: 12 Cases from a Single Institution Qian, Xiaoyuan Wang, Zhixian Zhang, Jiaqiao Wang, Qing Zhou, Peng Wang, Shaogang Wang, Bo Qian, Can Cancer Manag Res Original Research PURPOSE: Collecting duct carcinoma (CDC) is extremely rare and has high malignancy and poor prognosis. The purpose of this research is to explore the clinical characteristic, imaging, pathological diagnosis, treatment and prognostic outcome of CDCs. MATERIALS AND METHODS: The clinical data of 12 CDC cases who had been surgically treated between August 2007 and August 2017 and verified the diagnosis of CDC by postoperative pathological and/or immunohistochemical staining (IHC) results were retrospectively analyzed, and related works of literature were reviewed. And Kaplan-Meier survival analysis was used to draw the survival curve and to calculate the survival rate and the median survival time. RESULTS: According to the TNM stage system, 4 cases were in stage I, 2 in stage II,3 in stage III, and 3 in stage IV. On the computed tomograph and magnetic resonance imaging, CDC displayed that various shapes, unclear boundary and invasive growth into the renal parenchyma. Compared with small CDCs which did not change the contour of the kidney, large CDCs presented various imaging features. Microscopically, the typical morphology of CDCs was that collecting ducts or tubules were obviously infiltrated by tumor cells. A tubular, papillary, tubulopapillary or solid architectures with desmoplasia were often presented. And tumor cells had high-grade cytology or an infiltrative growth pattern. Necrosis of tumor cells also was common in many cases. The expression of biomarkers, such as PAX-8, INI-1, 34βE12, CK19, PAX-2, and vimentin, in most patients was detected by IHC. Eleven of all 12 cases received radical surgery, of whom 5 patients died 3–11 months after surgery, and 1 case having undergone interventional embolization therapy died at 6 months after treatment due to multiple metastases. And 1 lost to contact. The overall 1-, 2-, and 5-year survival rates were 45.5%, 36.4%, and 8.8%, respectively, and the median survival time (MST) was 11 months. CONCLUSION: CDC has an aggressive clinical course, with a poor prognosis. The best way to treat CDC suspected by imaging examinations is radical surgery which can contribute to confirm the correct histopathological type. And post-operation follow-up is necessary. Dove 2020-05-19 /pmc/articles/PMC7245445/ /pubmed/32547196 http://dx.doi.org/10.2147/CMAR.S244094 Text en © 2020 Qian et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Qian, Xiaoyuan
Wang, Zhixian
Zhang, Jiaqiao
Wang, Qing
Zhou, Peng
Wang, Shaogang
Wang, Bo
Qian, Can
Clinical Features and Prognostic Outcome of Renal Collecting Duct Carcinoma: 12 Cases from a Single Institution
title Clinical Features and Prognostic Outcome of Renal Collecting Duct Carcinoma: 12 Cases from a Single Institution
title_full Clinical Features and Prognostic Outcome of Renal Collecting Duct Carcinoma: 12 Cases from a Single Institution
title_fullStr Clinical Features and Prognostic Outcome of Renal Collecting Duct Carcinoma: 12 Cases from a Single Institution
title_full_unstemmed Clinical Features and Prognostic Outcome of Renal Collecting Duct Carcinoma: 12 Cases from a Single Institution
title_short Clinical Features and Prognostic Outcome of Renal Collecting Duct Carcinoma: 12 Cases from a Single Institution
title_sort clinical features and prognostic outcome of renal collecting duct carcinoma: 12 cases from a single institution
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245445/
https://www.ncbi.nlm.nih.gov/pubmed/32547196
http://dx.doi.org/10.2147/CMAR.S244094
work_keys_str_mv AT qianxiaoyuan clinicalfeaturesandprognosticoutcomeofrenalcollectingductcarcinoma12casesfromasingleinstitution
AT wangzhixian clinicalfeaturesandprognosticoutcomeofrenalcollectingductcarcinoma12casesfromasingleinstitution
AT zhangjiaqiao clinicalfeaturesandprognosticoutcomeofrenalcollectingductcarcinoma12casesfromasingleinstitution
AT wangqing clinicalfeaturesandprognosticoutcomeofrenalcollectingductcarcinoma12casesfromasingleinstitution
AT zhoupeng clinicalfeaturesandprognosticoutcomeofrenalcollectingductcarcinoma12casesfromasingleinstitution
AT wangshaogang clinicalfeaturesandprognosticoutcomeofrenalcollectingductcarcinoma12casesfromasingleinstitution
AT wangbo clinicalfeaturesandprognosticoutcomeofrenalcollectingductcarcinoma12casesfromasingleinstitution
AT qiancan clinicalfeaturesandprognosticoutcomeofrenalcollectingductcarcinoma12casesfromasingleinstitution